Glucose-6-phosphate: a key compound in glycogenosis I and favism leading to hyper- or hypolipidaemia.
The glycogen storage disorders (GSD)-I, -III, -VI and -VIII are associated with hypertriglyceridaemia or mixed hyperlipidaemia which poses the question whether these patients have an increased risk for atherosclerosis. The atherogenicity of triglycerides has remained controversial, while increased plasma cholesterol levels are generally accepted as a significant risk factor for coronary heart disease. However, clinical data show that one has to differentiate between metabolic conditions where triglycerides are atherogenic and those which are not significantly related to early onset of atherosclerosis but may cause other disorders such as pancreatitis. Among the disorders of carbohydrate metabolism patients with diabetes mellitus frequently have enhanced plasma triglycerides associated with a higher risk for coronary heart disease, while patients with certain types of glycogen storage disease have high triglyceride levels but do not seem to have an enhanced risk for atherosclerosis. Here we have compared the biochemical abnormalities and the atherogenic risk of three different disorders of glucose metabolism including GSD-I (glucose-6-phosphatase deficiency), favism (glucose-6-phosphate dehydrogenase deficiency), and diabetes mellitus which are related to either hyper- or hypolipidaemia. The available data indicate that glucose-6-phosphate (Glc-6-P) is a central molecule in cellular glucose metabolism which critically influences pentose phosphate cycle activity and, via NADPH2-generation, regulates glutathione peroxidase activity for radical detoxification and also cholesterol and triglyceride synthesis. Radical detoxification is a major protective factor for cell membrane integrity and together with an appropriate renewal of membrane lipids may protect against the development of atherosclerosis.(ABSTRACT TRUNCATED AT 250 WORDS)
Schmitz
G
G
Institut für Klinische Chemie und Laboratoriumsmedizin, Westfälische Wilhelms-Universität, Münster, Federal Republic of Germany.
Hohage
H
H
Ullrich
K
K
D001161:Arteriosclerosis / Q000209:etiology; D048909:Diabetes Complications; D005947:Glucose / Q000378:metabolism*; D019298:Glucose-6-Phosphate; D005955:Glucosephosphate Dehydrogenase Deficiency / Q000150:complications*; D005958:Glucosephosphates / Q000378:metabolism*; D005953:Glycogen Storage Disease Type I / Q000150:complications* / Q000378:metabolism; D006801:Humans; D006949:Hyperlipidemias / Q000209:etiology*; D006995:Hypobetalipoproteinemias / Q000378:metabolism; D007009:Hypolipoproteinemias / Q000209:etiology*; D008079:Lipoproteins, VLDL / Q000097:blood; D012307:Risk Factors
D005958:Glucosephosphates; D008079:Lipoproteins, VLDL; D019298:Glucose-6-Phosphate; D005947:Glucose